Madrigal pharmaceuticals announces three abstracts accepted by the liver meeting digital experience™, the american association for the study of liver diseases meeting in november 2020, including positive data from ongoing open label arm of resmetirom 52 w

Conshohocken, pa., oct. 01, 2020 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq:mdgl), announced today that, based on data from studies with mgl-3196 (resmetirom), three posters and an oral presentation of these data will be presented at the liver meeting digital experience™, the american association for the study of liver diseases meeting in november 2020. resmetirom is the first orally administered, small-molecule, liver-directed, truly Β-selective thyroid hormone receptor (thr) agonist and is currently in phase 3 development for the treatment of nash patients both with biopsy-confirmed fibrosis stage 2-3 (clinicaltrials.go v nct03900429) and in presumed nash subjects diagnosed non-invasively (clinicaltrials.g o v/nc t 04197479).
MDGL Ratings Summary
MDGL Quant Ranking